Patient-derived glioma models

Patient-derived glioma models

Patient-derived glioma models

3D Glioma model for personalized medicine

Tumors from individual patients respond with variable rates to therapy. This poses a significant challenge in the treatment of gliomas. For the purpose of screening patient-derived glioma tissues with potential therapeutic compounds, the Department of Neurosurgery of the ErasmusMC has developed a 2D culture platform (GLIOscreen). However, possibly also due to tumor heterogeneity, not all patient-derived glioma tissues are amenable to 2D culture. These hurdles highlight the need for complementary culture models. Here we show the development of an organotypic glioma model in OrganoPlates® to establish screenable cellular models for all glioma patients. This project is a collaboration between the ErasmusMC and Mimetas, the inventors of the OrganoPlate®.

Ultimately, the 3D glioma model will be used to culture individual patient’s cancer cells in a high throughput format for the screening of potential effective (combinatorial) treatments and personalized medicine.

The research is partially funded by foundation STOPhersentumoren.

Glioma cells seeded in three different ECMs
In figure 1: A glioma cell line GS365 and freshly dissected glioma material were seeded in three different ECMs (Matrigel, BME2reduced growth factor, collagen I) in the OrganoPlate® and cultured for 13 days. On day 13 cells were imaged with phase contrast and a live/dead cell viability assay (Life Technologies) was performed.

Temozolomide sensitivity

Temozolomide sensitivity of glioblastoma cells
In figure 2: GS203 and GS261 cells show a decrease in sensitivity to the first line therapy drug temozolomide (TMZ) when cultured in 3D (OrganoPlate®) compared to 2D (GLIOscreen) as determined with a fluorescent viability staining.